Neoantigen targeting autologous T cells (Genoimmune)

靶向新生抗原自体免疫T细胞（华大吉诺因）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNeoantigen targeting autologous T cells (Genoimmune)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsEsophageal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Ginoin Biotechnology Co LtdGenoimmune Therapeutics
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenzhen Ginoin Biotechnology Co LtdGenoimmune Therapeutics
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal NeoplasmsEsophageal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A